UPDATE: Cambridge Antibody Technology Partners with Immunex to Develop Drugs | GenomeWeb

NEW YORK, May 21 - Cambridge Antibody Technology will partner with Immunex to jointly discover and develop new antibody-based drugs for treating inflammation, the companies said Monday. 

The agreement calls for Immunex to provide two undisclosed protein drug targets and for CAT to develop antibodies to those targets using its antibody phage display and screening technologies. Immunex is to bear responsibility for pre-clinical evaluation, clinical trials, and product commercialization. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.